Ranbaxy shines with subsidiary’s launch of authorized version of Caduet in US

07 Dec 2011 Evaluate

Ranbaxy Laboratories is currently trading at Rs 442.00, up by 5.60 points or 1.28% from its previous closing of Rs 436.40 on the BSE.

The scrip opened at Rs 441.95 and has touched a high and low of Rs 444.10 and Rs 441.00 respectively. So far 27,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 611.75 on 04-Jan-2011 and a 52 week low of Rs 413.25 on 24-Nov-2011.

Last one week high and low of the scrip stood at Rs 483.95 and Rs 430.00 respectively. The current market cap of the company is Rs 18,652.00 crore.

The promoters holding in the company stood at 63.75% while Institutions and Non-Institutions held 20.50% and 14.00% respectively.

Ranbaxy Laboratories’ wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.

Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin. Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.

Recently, Ranbaxy Laboratories had received US health regulator’s approval to produce generic version of cholesterol lowering drug Lipitor, a move that will help the India-based firm to launch the drug in the American market.

Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.